CYP-mediated therapeutic protein-drug interactions: Clinical findings, proposed mechanisms and regulatory implications

Clinical Pharmacokinetics

Volumn 49, Issue 5, 2010, Pages 295-310

  Lee, Jang Ik ^a   Zhang, Lei ^a   Men, Angela Y ^a   Kenna, Leslie A ^a   Huang, Shiew Mei ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG; PROTEIN;

ANIMAL; BIOSYNTHESIS; DRUG EFFECT; DRUG INTERACTION; DRUG LEGISLATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; REVIEW; STANDARD; UNITED STATES;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LEGISLATION, DRUG; METABOLIC CLEARANCE RATE; PHARMACEUTICAL PREPARATIONS; PROTEINS; UNITED STATES;

EID: 79551588087     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11319980-000000000-00000     Document Type: Review

References (63)

1. United States Public Health Service Act, Section 351, 42 USC y 262 (1944)
2. United States Federal Food, Drug, and Cosmetic Act, Section 505, 21 USC y 355 (1938) [online]. Available from URL: http://www.fda.gov/opacom/laws/fdcact/ fdcact1.htm [Accessed 2010 Jan 25]
3. US FDA Center for Drug Evaluation and Research [CDER]. Guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling. Rockville (MD): CDER, 2006 Sep 11 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf [Accessed 2010 Jan 25]
4. Huang SM, Strong JM, Zhang L, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008; 48: 662-70
5. Huang SM, Temple R, Throckmorton DC, et al. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007; 81: 298-304
6. US FDA Center for Drug Evaluation and Research [CDER]. Drug development and drug interactions. Silver Spring (MD): CDER, 2009 Jul 23 [online]. Available from URL: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm [Accessed 2010 Jan 25]
7. Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for ther-apeutic monoclonal antibodies: reality check. J Clin Pharmacol 2007; 47: 1104-18
8. Mahmood I, Green MD. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol 2007; 47: 1540-54
9. Huang SM, Zhao H, Lee JI, et al. Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther 2010; 87: 497-503
10. Prandota J. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drugmetabolizing enzymes/cytokines may markedly contribute to this pathology. Am J Ther 2005; 12: 254-61
11. Morgan ET. Regulation of cytochromes P450 during inflammation and in-fection. Drug Metab Rev 1997; 29: 1129-88
12. Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008; 36: 205-16
13. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 2009; 85: 434-8
14. Chang KC, Bell TD, Lauer BA, et al. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1978; 1: 1132-3
15. Kraemer MJ, Furukawa CT, Koup JR, et al. Altered theophylline clearance during an influenza B outbreak. Pediatrics 1982; 69: 476-80
16. Renton KW, Deloria LB, Mannering GJ. Effects of polyribonoinosinic acid polyribocytidylic acid and a mouse interferon preparation on cytochrome P-450-dependent monooxygenase systems in cultures of primary mouse hepatocytes. Mol Pharmacol 1978; 14: 672-81
17. Mayo PR, Skeith K, Russell AS, et al. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol 2000; 50: 605-13
18. Strehlau J, Pape L, Offner G, et al. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet 2000; 356: 1327-8
19. Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 2006; 46: 123-49
20. Ashino T, Oguro T, Shioda S, et al. Involvement of interleukin-6 and tumor necrosis factor alpha in CYP3A11 and 2C29 down-regulation by Bacillus Calmette-Guerin and lipopolysaccharide in mouse liver. Drug Metab Dispos 2004; 32: 707-14
21. El-Kadi AO, Bleau AM, Dumont I, et al. Role ofreactive oxygen intermediates in the decreaseofhepatic cytochrome P450 activitybyserumofhumans and rabbits with an acute inflammatory reaction. Drug Metab Dispos 2000; 28: 1112-20
22. Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 2001; 92: 147-63
23. Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet 1987; 330: 939-41
24. Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol 1986; 22: 610-2
25. Becquemont L, Chazouilleres O, Serfaty L, et al. Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Clin Pharmacol Ther 2002; 71: 488-95
26. Pageaux GP, le Bricquir Y, Berthou F, et al. Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1998; 10: 491-5
27. Islam M, Frye RF, Richards TJ, et al. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 2002; 8: 2480-7
28. Craig PI, Tapner M, Farrell GC. Interferon suppresses erythromycin metab-olism in rats and human subjects. Hepatology 1993; 17: 230-5
29. Wong SF, Jakowatz JG, Taheri R. Potential drug-drug interaction between interferon alfa-2b and gemfibrozil inapatient with malignant melanoma. Clin Ther 2005; 27: 1942-8
30. Okuno H, Takasu M, Kano H, et al. Depression of drug-metabolizing activity in the human liver by interferon-beta. Hepatology 1993; 17: 65-9
31. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 2007; 35: 1687-93
32. Elkahwaji J, Robin MA, Berson A, et al. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol 1999; 57: 951-4
33. Tinel M, Robin MA, Doostzadeh J, et al. The interleukin-2 receptor down-regulates the expression of cytochrome P450 in cultured rat hepatocytes. Gastroenterology 1995; 109: 1589-99
34. Frye RF, Schneider VM, Frye CS, et al. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 2002; 8: 315-9
35. Chen YL, Le Vraux V, Leneveu A, et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994; 55: 649-60
36. Knupfer H, Schmidt R, Stanitz D, et al. CYP2C and IL-6 expression in breast cancer. Breast 2004; 13: 28-34
37. Gorski JC, Hall SD, Becker P, et al. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther 2000; 67: 32-43
38. Glassman AH, Johnson LL, Giardina EG, et al. The use of imipramine in depressed patients with congestive heart failure. JAMA 1983; 250: 1997-2001
39. Winkelhake JL, Gauny SS. Human recombinant interleukin-2 as an experi-mental therapeutic. Pharmacol Rev 1990; 42: 1-28
40. Moore KW, O'Garra A, de Waal MR, et al. Interleukin-10. Annu Rev Im-munol 1993; 11: 165-90
41. Sifontis NM, Benedetti E, Vasquez EM. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant Proc 2002; 34: 1730-2
42. Vasquez EM, Pollak R. OKT3 therapy increases cyclosporine blood levels. Clin Transplant 1997; 11: 38-41
43. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [published erratum appears in N Engl J Med 1989; 321: 63].
44. N Engl J Med 1989; 320: 1420-1
45. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606-8
46. Hoffmann-La Roche Inc. Briefing document for tocilizumab biologic license application 125276. Nutley (NJ): Hoffmann-La Roche Inc., 2008 Jul 2 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4371b1- 02-Roche.pdf [Accessed 2010 Jan 25]
47. Zhang X, Achmitt S, Grange S, et al. Disease-drug interaction studies of tocilizumab with cytochrome P450 substrates in vitro and in vivo [abstract]. Clin Pharmacol Ther 2009; 85: S59
48. Actemra® (tocilizumab): package insert. South San Francisco (CA): Genentech Inc., 2010 Jan 10 [online]. Available from URL: http://www.accessdata. fda.gov/drugsatfda-docs/label/2010/125276lbl.pdf [Accessed 2010 Mar 21]
49. Jurgens G, Lange KH, Reuther LO, et al. Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men. Clin Pharmacol Ther 2002; 71: 162-8
50. Cheung NW, Liddle C, Coverdale S, et al. Growth hormone treatment in-creases cytochrome P450-mediated antipyrine clearance in man. J Clin Endocrinol Metab 1996; 81: 1999-2001
51. Levitsky LL, Schoeller DA, Lambert GH, et al. Effect of growth hormone therapy in growth hormone-deficient children on cytochrome P-450-dependent 3-N-demethylation of caffeine as measured by the caffeine 13CO2 breath test. Dev Pharmacol Ther 1989; 12: 90-5
52. Redmond GP, Bell JJ, Perel JM. Effect of human growth hormone on amobarbital metabolism in children. Clin Pharmacol Ther 1978; 24: 213-8
53. Redmond GP, Bell JJ, Nichola PS, et al. Effect of growth hormone on human drug metabolism: time course and substrate specificity. Pediatr Pharmacol (New York) 1980; 1: 63-70
54. Roferon®-A (interferon alfa-2a, recombinant): package insert. Nutley (NJ): Hoffman La Roche Inc., 2006 Aug 29 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/103145s5060LBL.pdf [Accessed 2010 Jan 25]
55. Jonkman JH, Nicholson KG, Farrow PR, et al. Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol 1989; 27: 795-802
56. Intron® A (interferon alfa-2b, recombinant for injection): package insert. Kenilworth (NJ): Schering Corporation, 2007 Jul 13 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/ 103132s5096lbl.pdf [Accessed 2010 Jan 25]
57. PegIntron (peginterferon alfa-2b injection, powder for solution for sub-cutaneous use): package insert. Kenilworth (NJ): Schering Corporation, 2009 Mar 10 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda- docs/label/2009/103949s5172lbl.pdf [Accessed 2010 Jan 25]
58. Arcalyst® (rilonacept injection for subcutaneous use): package insert. Tarry-town (NJ): Regeneron Pharmaceuticals, Inc., 2008 Feb 27 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/ 125249lbl.pdf [Accessed 2010 Jan 25]
59. Ilaris® (canakinumab): package insert. East Hanover (NJ): Novartis Phar-maceuticals Corp., 2009 Jun 17 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125319s000lbl.pdf [Accessed 2010 Mar 21]
60. Simponi® (golimumab): package insert. Horsham (PA): Centocor Ortho Biotech Inc., 2009 Nov 18 [online]. Available from URL: http://www.accessdata. fda.gov/drugsatfda-docs/label/2009/125289s006lbl.pdf [Accessed 2010 Mar 21]
61. Stelara® (ustekinumab): package insert. Horsham (PA): Centocor Ortho Biotech Inc., 2009 Dec 30 [online]. Available from URL: http://www.accessdata. fda.gov/drugsatfda-docs/label/2009/125261s001lbl.pdf [Accessed 2010 Mar 21]
62. Drugs@FDA: somatropin package inserts [online]. Available from http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Accessed 2010 Jan 25]
63. Zhang L, Zhang YD, Zhao P, et al. Predicting drug-drug interactions: an FDA perspective. AAPS J 2009; 11: 300-6